Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

Compositions, articles and methods for treating sleeplessness, anxiety, pain or inflammation include: (i) one or more pharmacologically active, non-psychoactive cannabinoids; (ii) one or more active agents; and an optional carrier or matrix. The optional carrier or matrix may comprise ingredients such as solvents, solid or dissolvable supports, fillers, flavorants, flavor or taste masking agents, and other adjuvants that provide the composition in a useful form factor configured for easy administration to a mammal of an appropriate pharmacological dosage of the active ingredients.

The disclosure herein are materials and methods for the treatment of snake bite. Aspects of the disclosure includes pharmaceutical compositions, and kits, both of which may be of use in the treatment of snake bite.

The disclosure herein are materials and methods for the treatment of snake bite. Aspects of the disclosure includes pharmaceutical compositions, and kits, both of which may be of use in the treatment of snake bite.

The present invention includes compositions and methods for treating a proliferative disease in a patient that comprises administering to the patient a therapeutically effective amount of 2,4-Disulfonyl-N-Tert-Butylnitrone, 2,4-disulfonyl α-phenyl tertiary butyl nitron or a pharmaceutically acceptable salt thereof.

Embodiments of the invention relate generally to formulations comprising dimethyl sulfoxide (DMSO) to treat behavioral disorders, communication delays, and developmental delays. Several formulations disclosed herein are useful for treating broad autism phenotype disorders, including autism spectrum disorders (e.g., autism).

Embodiments of the invention relate generally to formulations comprising dimethyl sulfoxide (DMSO) to treat behavioral disorders, communication delays, and developmental delays. Several formulations disclosed herein are useful for treating broad autism phenotype disorders, including autism spectrum disorders (e.g., autism).

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.

In some aspects, disclosed herein are methods and compositions for treatment or prevention of cerebral palsy using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neurogenesis and/or reducing inflammation in a subject. In some cases, the disclosed methods comprise use of conditioned fibroblasts. Fibroblasts may be conditioned with agents capable of enhancing therapeutic efficacy, for example oxytocin and/or human chorionic gonadotrophin (hCG).